Opus Investment Management Inc. lifted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 5.6% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 37,600 shares of the medical research company’s stock after buying an additional 2,000 shares during the period. Amgen comprises 1.1% of Opus Investment Management Inc.’s investment portfolio, making the stock its 11th largest position. Opus Investment Management Inc.’s holdings in Amgen were worth $6,476,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Camelot Portfolios LLC purchased a new position in Amgen in the 1st quarter worth approximately $1,429,000. PGGM Investments increased its stake in Amgen by 2.3% in the 2nd quarter. PGGM Investments now owns 670,936 shares of the medical research company’s stock worth $115,555,000 after purchasing an additional 15,059 shares during the period. Shelton Capital Management increased its stake in Amgen by 82.7% in the 1st quarter. Shelton Capital Management now owns 108,997 shares of the medical research company’s stock worth $17,883,000 after purchasing an additional 49,354 shares during the period. Greylin Investment Mangement Inc. increased its stake in Amgen by 466.9% in the 2nd quarter. Greylin Investment Mangement Inc. now owns 14,030 shares of the medical research company’s stock worth $2,416,000 after purchasing an additional 11,555 shares during the period. Finally, Kelman Lazarov Inc. increased its stake in Amgen by 8.2% in the 2nd quarter. Kelman Lazarov Inc. now owns 1,580 shares of the medical research company’s stock worth $272,000 after purchasing an additional 120 shares during the period. 78.10% of the stock is currently owned by institutional investors.
A number of equities analysts have commented on the company. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and issued a $203.00 price target on shares of Amgen in a research note on Friday, October 6th. Mizuho reaffirmed a “buy” rating and issued a $198.00 price target on shares of Amgen in a research note on Friday, October 6th. Morgan Stanley reaffirmed an “overweight” rating and issued a $196.00 price target (up from $189.00) on shares of Amgen in a research note on Friday, October 6th. Cann reaffirmed a “buy” rating and issued a $203.00 price target on shares of Amgen in a research note on Friday, October 6th. Finally, Bank of America Corporation lifted their price target on Amgen to $210.00 and gave the stock a “buy” rating in a research note on Thursday, October 5th. Ten research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have given a strong buy rating to the company’s stock. Amgen presently has a consensus rating of “Buy” and an average target price of $189.99.
Shares of Amgen Inc. (NASDAQ:AMGN) opened at 185.79 on Wednesday. The company’s 50 day moving average price is $182.35 and its 200 day moving average price is $170.56. The company has a market capitalization of $135.57 billion, a price-to-earnings ratio of 16.92 and a beta of 1.36. Amgen Inc. has a 52-week low of $133.64 and a 52-week high of $191.10.
Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, topping the consensus estimate of $3.11 by $0.16. The company had revenue of $5.81 billion for the quarter, compared to the consensus estimate of $5.67 billion. Amgen had a return on equity of 29.85% and a net margin of 35.46%. Amgen’s quarterly revenue was up 2.1% on a year-over-year basis. During the same period last year, the business posted $2.84 EPS. On average, analysts predict that Amgen Inc. will post $12.58 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://sportsperspectives.com/2017/10/11/opus-investment-management-inc-increases-position-in-amgen-inc-amgn.html.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction on Monday, October 9th. The stock was sold at an average price of $185.95, for a total transaction of $283,573.75. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.19% of the company’s stock.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.